Greetings, and welcome to the CryoLife Fourth Quarter and Year End 2009 Financial Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder this conference is being recorded. It is now my pleasure to introduce your host, Steve Anderson, President and CEO for CryoLife. Thank you. Mr. Anderson, you may begin.

Good morning, everyone. This is Steve Anderson, the CEO of CryoLife and I would like to welcome you all to our earnings conference call for the fourth quarter and fiscal year of 2009. With me today is Ashley Lee, the Company’s Executive Vice President, CFO, and COO. This morning we announced our results for fiscal year 2009. We were very pleased to announce record revenues of a $111.7 million and record operating income of $14.5 million. The fourth quarter represented the 12th consecutive quarter of profitability for the company and the third consecutive year of profitability. Considering the economic environment that we have been operating in for the last two years, I’m very pleased with this performance. The agenda for today’s call is as follows. Ashley will discuss the fourth quarter and the yearly operating results in detail. He will bring you up to-date on our progress on the potential acquisition of Medafor. I will discuss the CE Mark approval for BioFoam in Europe, as well as milestones reached in the prospective European study and the market launch of BioFoam in Europe in January. I will also discuss the timing of the IDE PMA for BioFoam in the U.S. After my comments have concluded, Ashley will return to give you some financial guidance for the rest of the year. When Ashley has completed his guidance comments, I will return to make some comments directly to the Medafor shareholders who are listening to this call. If there is time left after my concluding comments, we will open up the call for questions. At this time, Ashley will discuss this morning’s press release.

Thanks, Steve. To comply with the Safe Harbor requirements of the Private Securities Litigation Reform Act of 1995, I would like to make the following statement. Comments made in this call, which look forward in time, involve risk and uncertainties and our forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements include statements made as to the company’s or management’s intentions, hopes, beliefs, expectations or predictions of the future. Additional information concerning risk and uncertainties that may impact these forward-looking statements is contained from time-to-time in the company’s SEC filings including the risk factor section of our Form 10-K for the year ended December 31, 2009, which we expect to file by the end of this week and in the press release that went out this morning, a copy of which has contained on the Investor Relations portion of our website. This morning we reported our results for the fourth quarter and full year 2009. We set an all time quarterly revenue record of $28.6 million in the fourth quarter of ‘09 and an all time full year revenue record of a $111.7 million. These amounts were 12% and 6% higher in the corresponding periods in 2008. Our cash and marketable securities balances increased to $35.1 million at December 31, ‘09, an increase of $12.4 million, compared to December 31 of ‘08. Currently, our cash and marketable securities balances stand at over $35 million. We also purchased $4.8 million of Medafor common stock during the fourth quarter of ‘09 in early 2010, and this amount is not included in our cash and investment balances. Net income for the fourth quarter of ‘09 was $2.4 million or $0.08 per basic and fully diluted common share, excluding a pre-tax charge of $377,000 related to…

During December, we completed the initial Phase of our prospective European study for BioFoam when you use to seal parenchymal tissues, which is liver and spleen. Clinical results were analyzed for the first 31 patients enrolled, showing an average meantime to homeostasis of less than two minutes, and an adverse event rate within reported percentages for liver surgery. To-date BioFoam has been used in more than 50 patients at three clinics in France, Germany, and the U.K.. We anticipate adding a fourth centre in Germany in February and should reach our target enrollment of 70 patients for this study in May of 2010. BioFoam has proven itself to be a highly effective hemostatic agent. BioFoam was commercially launched in the European community in January at the company’s yearly sales kickoff meeting of our direct sales forces, as well as distributors that was held this year in Rome. The launch will focus initially on our direct sales forces that are in the U.K. and in Germany, in an effort to leverage the clinical experience gained in the prospective study sites. We anticipate that we will realize the first sales of BioFoam other than for used in the clinical study sometime this month. During feasibility animal testing of BioFoam, it was found that it was effective in controlling bleeding at systemic cardiovascular blood pressures. Following additional preclinical testing, we expect to submit a CE Mark application for this expanded clinical use of BioFoam in cardiovascular surgery to our European Notified Body in the fourth quarter of 2010. Management believes that the market for BioFoam addresses for cardiovascular surgical use in international markets is about a $100 million. Using BioFoam for cardiovascular indications has various advantages for the patient and the doctor. First of all, BioFoam is more viscous as compared to the…

Thanks, Steve. We expect another record year of revenues and operating profit for 2010. We expect total revenues for the full year of 2010 to be between $118 and $123 million, which includes between $1.5 and $2.5 million related to funding received from the department of defense in connection with the development of BioFoam. We expect tissue-processing revenues and BioGlue revenues to each increase between mid-single and low double digits on a percentage basis in 2010 compared to 2009, the HemoStase revenues increasing significantly more than that on a percentage basis. Although during 2010, we expect to pay cash for income taxes at a rate somewhat closer to our effective income tax rate of 41%. We believe that we will continue to generate significant operating cash flow during 2010. We expect earnings per share up between $0.36 and $0.40 for 2010. Our earnings guidance contains general expenses associated with business development opportunities, but does not include significant expenses associated with specific targets, such as Medafor or potential changes in the value of the Medafor-related derivative. Depending upon our course of action and the ultimate result of those actions, such as a proxy contest or the completion of an acquisition, we could incur expenses or changes in the value of the derivative that could materially affect our guidance. There are also few items that I would like to comment on that I believe could be positive developments for the company in the future. A sequence in earlier, we expect to begin enrolling patients in our BioFoam IDE a little later this year under an FDA approved clinical trail. This will be the first step in getting a commercial approval to distribute BioFoam in the U.S. We are still optimistic that we will get approval to sell BioGlue in Japan. Progress continues…

I would like to make a few comments to the Medafor shareholders that are listening to our conference call today. As Ashley said, we think that a combination of CryoLife and Medafor provides an excellent opportunity for shareholders of both Companies. We believe Medafor’s technology has a great deal of promote [ph], but that the company faces a number of significant challenges that will keep it from maximizing this potential. Challenges we don’t think it can address on its own. We have made a proposal for Medafor because we think we are strong in areas where Medafor is weak and that we can help Medafor overcome its challenges. The Medafor bore it’s present stand of not even talking to us, denies Medafor shareholders of the opportunity to even explore the possibility of a business combination for CryoLife. Whether Medafor’s management likes it or not, the reality is that CryoLife’s 11% stake in Medafor, the two companies are business partners and we will assert our rights as their largest shareholder. Medafor’s difficulty in securing working capital is a good illustration of a weakness we can help the company to overcome. Over the last two years, Medafor’s management has attempted to secure more working capital in order to access better cash flow. This isn’t very difficult for management to accomplish because of the financial environment in the United States and the liquidity issues facing the company. Medafor has been further hindered by ongoing concern letter issued to the company in September 20, ’09, by KFPMG Medafor’s auditor in connection with their 2008 audit of Medafor. A letter like this is issued by an accounting firm when they feel that the company may not have the capital resources to survive for the next 12 months. Both of these situations have negatively affected management’s…

Thank you. We will now be conducting a question-and-answer session. (Operator Instructions). Thank you. Our first question is coming from Mr. Matt Dolan of Roth Capital. Matthew Dolan – Roth Capital Partners: Hi guys. Good morning. This is Matt Dolan.

Good morning.

Hi Matt. Matthew Dolan – Roth Capital Partners: Let’s see. So looking at your guidance for the year, you are looking at mid-single to low double-digit growth for both preservation and BioGlue, which requires an acceleration in growth rates. And - that we saw for both these segments in 2009, can you walk us through some of the challenging issues like inventory destocking, and pricing that you experienced in 2009? And how you’re expecting these to improve to achieve your guidance in 2010?

Yeah. I think some of the destocking issues that you refer to were really more evidenced in the early part of 2009. And as the year went on, Matt we saw those issues kind of resolve themselves, and we believe that our customers returned to a more normal purchasing pattern as the year went on. So that bodes well for both of those businesses with tissues and BioGlue as we move forward into 2010. The pricing question that that you had, we saw pricing pressure really start to develop in late 2008, and into 2009, and we continue to see that throughout 2009. I think those are issues that that we as a industry are going to have to deal with going forward, but it really hasn’t hurt our ability to continue growing our business as evidenced with what we saw in the fourth quarter and based on what we’re seeing early so far this year in 2010 we’re optimistic that we are going to be within the range of guidance that we’ve provided for. Matthew Dolan – Roth Capital Partners: Okay, great. And secondly on with regard to your $2 million in cost savings, maybe you can give us some commentary on where you’ve been able to make these cuts?

They were throughout the organization. Specifically referring back to the reduction in force and related savings, we really took a comprehensive look at all of our operations and despite the fact that we had a very, very good year in 2009, and expected another in 2010. We want to make sure that our business is running as efficiently as possible. So we took a thorough look at our entire business and it’s really – if there is probably one area more than others, it was probably the tissue processing area and the manufacturing areas, but there was really no area within the company that was untouched by the process that we went through. Matthew Dolan – Roth Capital Partners: That’s helpful. And a two-part question on Medafor, assuming they remain unresponsive, can you elaborate on your plans and the timeline of those plans, as you continue to pursue this acquisition? And secondly on a broader basis how important is HemoStase to your long-term growth potential in your view?

I’ll answer the first question first. You know, we’ve stated publicly in the letter that we sent to their Board earlier this week, and in our comments earlier today that we have options available to us. But you know, first and foremost, we would like to enter into discussions with them about our proposal to combine the companies. And that would be our first preference. But again, in the event that we are not successful in doing that, we have outlined that we do have some options that are available to us, including calling a special shareholders meeting, launching a proxy fight and potentially a tender offer. We have no set timelines for any of those particular options but you know, we’re going to evaluate all of them and when we act the public will know. Your second question again. Matthew Dolan – Roth Capital Partners: The long-term growth potential that HemoStase adds to your -- how important is HemoStase to your long-term growth potential?

Well, we certainly think it’s a very, very good technology. We think it’s got a ton of potential and as evidenced by the fact that we made a proposal to combine our companies. But as we’ve stated in the past, we continue to look at other opportunities to grow our business. We have a lot of products in development right now that we think are going to be coming to fruition over the next two to four years, and we continue to look at other business development opportunities. Even as we pursue Medafor at this time, we continue to look at other business opportunities. So we think that the growth prospects are good with Medafor, and even without, we continue to look at ways to continue growing our business.

We are looking at HemoStase as a product platform, not just a product, but a product platform, and Dr. Drake with whom we have the - that exclusive agreement has always been very bullish on his ability to create many new products using that basic technology and we'd like to get started on that as quickly as possible. Matthew Dolan – Roth Capital Partners: Okay. That’s very helpful. Thank you for taking the questions.

Sure. I think there is no more…

Our next question is coming from Mr. Greg Brash of Sidoti & Company. Greg Brash – Sidoti & Company: Steve and Ashley, thanks for taking my call.

Hi Greg. Greg Brash – Sidoti & Company: Just wanted to clarify one more on Medafor. If this thing deal doesn't end up going through, there shouldn’t be any issues with your ability to distribute the product and it should still be your option to renew when the deal ends, assuming you keep hitting the minimum purchase agreements. Am I correct on that?

That’s correct. Our current agreement runs through the middle of next year and assuming that we continue to meet our purchase requirements, which we have done to-date, then the agreement would renew for another three years. Greg Brash – Sidoti & Company: Okay. And then on BioGlue, I don't know if I missed it, if you broke out unit versus ASP growth order?

If you look at the fourth quarter compared to the third quarter first, we were up about 12% sequentially from the third to the fourth quarter. Year-over-year we were up about 4% in the fourth quarter compared to the fourth quarter of 2008. And a lot of the growth in the fourth quarter of ’09 compared to ’08 was ASP driven as opposed to unit driven. Greg Brash – Sidoti & Company: Okay. Just curious, some of the trends you saw last quarter with BioGlue, less off label use competitive pressure, possible curtailing use of surgical sealants, has that improved at all?

Any information that we have about that is really anecdotal. What we really saw in the fourth quarter was just a renewed focus on BioGlue, and going back to your customer base and reminding them of the benefits of the product. And it's really just sales effort that really got the results in the fourth quarter. And again we expect to see continued growth into 2010. Greg Brash – Sidoti & Company: Okay. And – and just regarding your tissue processing margins, I guess when can we expect that to start to improve again?

We think that, as we go into 2010 that tissue processing gross margins could be under a little bit more pressure. But we expect -- but not significant -- but we expected that by middle of the year that should start stabilizing and in the latter part of this year, we think that there is actually a little bit room for improvement in tissue processing gross margins. And then the other thing to consider in the aggregate about overall gross margin is that HemoStase carries gross margins of between 55% and 60% and as that continues to become a more significant part of our business that’s going to have a little bit of an affect to put a little bit of downward pressure on overall gross margins, but again all of that has been already accounted for in the bottom-line guidance that we gave for 2010. Greg Brash – Sidoti & Company: Okay. Regarding BioFoam seems like you are going to start shipping product in Europe within the next month. Just curious, what you have included in your guidance from BioFoam and are you going to be breaking that out on future conference calls?

We haven’t included a lot in 2010 for BioFoam. We’re very early in the launch, and don’t want to give out specific guidance. We want to see how the roll out goes, we’re very optimistic about it, but that’s all included in the product revenue guidance that we gave for 2010. Greg Brash – Sidoti & Company: Okay, just one final from me. I think you mentioned you bought 4.8 million shares with Medafor, just curious what was that what was the total dollar amount?

That was the dollar amount. Greg Brash – Sidoti & Company: Okay.

Yeah, that was the dollar amount. Greg Brash – Sidoti & Company: Thank you.

Thank you. Our next question is coming from Mr. Raymond Myers with Emerging Growth Equities.

Thanks and congratulations on the progress.

Thanks and congratulations on the progress.

Hello, Ray, how are you?

Hi. Doing well. First, you didn’t touch upon your progress with these getting the extended shelf life SynerGraft. Where does stand?

Hi. Doing well. First, you didn’t touch upon your progress with these getting the extended shelf life SynerGraft. Where does stand?

We are still currently in discussions with the FDA right now. We had discussions with them they’ve requested some more data. So that’s an ongoing process. And we really don’t have it depend as the time line may soon we can expect that.

We did find about 30 I believe above that we have been stored in research that have been stored for five years. And they were processed with the SynerGraft process. And so we are in the process of accumulating the data, and testing all of those valves. So that report that will be sent to the FDA as soon as that work has done. It will be very comprehensive, and it should answer all of their questions and concerns.

Great. And there is reason to believe that after five years, that there are still in fact viable?

Great. And there is reason to believe that after five years, that there are still in fact viable?

Yes.

Good, good. And also you made a mention that you did expect to get BioGlue Japan approval at some point. Can you put a little timeframe around there?

Good, good. And also you made a mention that you did expect to get BioGlue Japan approval at some point. Can you put a little timeframe around there?

I don’t to want to put a timeframe around, Ray. We continue to make progress. We continue to remain optimistic that we are going to get an approval. It could potentially happen this year, but then again it might not, but from the progress that’s been made, we continue to remain optimistic that we're going to get an approval, and we have not included anything in our guidance associated with the potential approval.

Good. And then Steve, I want to compare your comments about the HemoStases time for BioFoam in the later recession study. This time you said less than two minutes. In November you said that 19 patients had been tested, and successful HemoStase is in under one minute? Is there been a change?

Good. And then Steve, I want to compare your comments about the HemoStases time for BioFoam in the later recession study. This time you said less than two minutes. In November you said that 19 patients had been tested, and successful HemoStase is in under one minute? Is there been a change?

Really it hasn’t thing is we just have more patient that were looking at. I think we now have 50 patients, and it just depends on how serious, how big rather the last duration is or how big the removal of a tumor is. So it's changed a little bit, but it’s still very, very good. That's a very vascular organ, and to be able to do with that quickly is very positive.

Right. And help us to understand what that means, one minute or two minutes, as compared to what. My understanding is that currently it’s almost impossible to stop the bleeding.

Right. And help us to understand what that means, one minute or two minutes, as compared to what. My understanding is that currently it’s almost impossible to stop the bleeding.

Yes it’s very hard to suture an organ. I understand and we have seen films here that were taken during the procedures in Europe, and it’s very effective, and really pretty instantaneously stopping copious amounts of blood flow. So we’re very positive about that product and the doctors that have used it are very positive about it.

Good. I just wanted to put that into context. And then your current sales force, how big is that now?

Good. I just wanted to put that into context. And then your current sales force, how big is that now?

Give me a sec. About 50.

So, roughly flat?

So, roughly flat?

You know about 50.

Yes, okay good. And then just commenting on Medafor, I understand that it’s a great platform, and hopefully you - the parties can come together on that. But it seems like we’ve got an awful lot of focus on Medafor. And there are other HemoStase’s[Author ID1: at Tue Mar 2 21:14:00 2010 ] technologies out there. And I would imagine for the amount of money that you’re contemplating spending on Medafor that there are other alternatives. I hope we are pursuing those simultaneously?

Yes, okay good. And then just commenting on Medafor, I understand that it’s a great platform, and hopefully you - the parties can come together on that. But it seems like we’ve got an awful lot of focus on Medafor. And there are other HemoStase’s[Author ID1: at Tue Mar 2 21:14:00 2010 ] technologies out there. And I would imagine for the amount of money that you’re contemplating spending on Medafor that there are other alternatives. I hope we are pursuing those simultaneously?

Ray, as I mentioned earlier. We are obviously focused on Medafor and a potential combination within. But referring back to our comments that I made earlier, we continue to pursue other business development opportunities. Our pursue of Medafor is not interfering with that process, and we continue to move forward. Raymond Myers – Emerging Growth Equities: And so by the middle of next year if you were to go with another technology, you could walk away from the Medafor contract without any obligation.

Well again, I’ll reiterate that that we would prefer to enter into discussions with Medafor, and about our proposal to combine with that organization, we think that it could create a lot of value for both Medafor shareholders and CryoLife shareholders. And we demonstrated that that we are committed to doing that. I guess, but from an actual standpoint, we could walk away at the middle of next year, but we have no clients to do that. Raymond Myers – Emerging Growth Equities: Okay, great. So, I think the cursor is in your hands. Thank you.

Thank you. At this time, there is no further time for question. I will turn the floor back over to Mr. Anderson.

Thank you for joining us today. And we look forward in talking with you again after the completion of our first quarter.